Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 22, 2018
Pharmacy Choice - News - Pharmaceutical Development - February 22, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/22/18 - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the fourth quarter and year-ended December 31, 2017, on Thursday, March 1, 2018, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/ 2:00 p.m. Pacific
2/21/18 - AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
AbbVie, a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc., announced that the Phase 3 ELARIS UF-I study of elagolix met its primary endpoint. Uterine fibroids are the most common type of abnormal growth in a woman's pelvis and can affect up to 80 percent of women by age 50. 1 Fibro
2/21/18 - AbbVie doubles down on tau with Voyager Alzheimer`s deal [Arab News (Saudi Arabia)]
AbbVie has teamed up with Voyager Therapeutics on a tau protein-targeting program, paying $69 million upfront for an option on the Alzheimers disease candidate. According to AbbVie, that approach would have dosing advantages over current tau-targeting drugs in the industrys pipeline that could translate into a higher chance of showing efficacy.
2/21/18 - AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
AbbVie presented new positive results from clinical trials that evaluated risankizumab compared to placebo or ustekinumab, at the 2018 American Academy of Dermatology Annual Meeting in San Diego.
2/21/18 - AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer
BARCELONA, Catalonia, Spain- Ability Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration has approved a phase 1/ 2 study to assess the efficacy and safety of ABTL0812 in combination with gemcitabine and nab-paclitaxel in patients with advanced metastatic pancreatic cancer at first line
2/21/18 - ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27 2018
SAN DIEGO- ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2017 on Tuesday, February 27,
2/21/18 - Achieve Announces Preliminary Data from Cytisine Phase I II Multi-Dose Pharmacokinetic and Pharmacodynamics Clinical Study
BOTHELL, Washington and VANCOUVER- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced preliminary data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics clinical study of cytisine.
2/21/18 - Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
By a News Reporter-Staff News Editor at Biotech Week Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under "Investor Events" in the Investor section of the
2/21/18 - Aimmune shares surge as PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch [Sport360]
Four months after DBV Technologies stock was crushed by a shaky set of pivotal data for its peanut allergy drug, rival Aimmune Therapeutics$ AIMT says its Phase III has come through with a promising set of results. And the win sets up an FDA application later this year for the pioneering drug, with a European pitch to follow soon after. Its great t
2/21/18 - Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Aldeyra Therapeutics, Inc., a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that the results of the Phase 2 a clinical trial of topical ocular reproxalap in dry eye disease were selected for podium presentation at the 2018 Association for Rese
2/21/18 - Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies
Arix Bioscience plc, a global healthcare and life science company supporting medical innovation, and Ipsen, a global specialty-driven biopharmaceutical company focused on innovation and specialty care, today announced a strategic agreement to develop and commercialise innovative therapies. Arix will provide Ipsen with access to its unique network o
2/21/18 - Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
COPENHAGEN, Denmark- Ascendis Pharma A/S, a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis. J.P. Morgan Securities LLC, BofA Merrill Lynch and Credit Suisse Securities LLC are acting
2/21/18 - Ascendis Pharma A/S Announces Proposed Public Offering of ADSs [Tehran Times (Iran)]
-Ascendis Pharma A/S, a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis. J.P. Morgan Securities LLC, BofA Merrill Lynch and Credit Suisse Securities LLC are acting as joint book-runni
2/21/18 - Ascentage Pharma to Present at the IASLC 18th Lung Cancer Targeted Therapies Meeting
ROCKVILLE, Md. and HONG KONG, Feb. 21, 2018/ PRNewswire-USNewswire/ Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the presentation of preliminary data from its ongoing Phase 1 trials of its lead product candidate APG-1252, a
2/21/18 - AstraZeneca - US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
2/21/18 - Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
Avid Bioservices, Inc., a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that Enzyvant, a subsidiary of Roivant Sciences, has selected Avid as the commercial drug substance manufacturer for RVT-801, its recombinant human acid cerami
2/21/18 - Avid offloads Phase III mAb, becomes pureplay CDMO [Algeria Press Service]
In November last year, Peregrine Pharmaceuticals called time on its in-house biologics pipeline in favour of focusing on and growing its contract development and biomanufacturing business, Avid Bioservices. Now having dropped the Peregrine name the firm has entered an agreement to sell its phosphatidylserine- targeting programme including lead...
2/21/18 - BioArctic Receives Regulatory Approval in Estonia for a Clinical Study in Patients With Complete Spinal Cord Injury
BioArctic AB announced today that the company has received approval by the Estonian State Agency of Medicines, the Estonian Health Board for medical device and the local ethics committee for inclusion of Estonian patients in BioArctic's ongoing clinical Phase 1/ 2 study with SC0806. Our ambition is to develop SC0806 to improve the quality of life f
2/21/18 - BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome MPS IIIB at WORLDSymposium? 2018
By a News Reporter-Staff News Editor at Biotech Week BioMarin Pharmaceutical Inc. announced that it presented interim data from a Phase 1/ 2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetylglucosaminidase with a peptide derived from insulin-like growth factor 2, for the trea
2/21/18 - BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference
By a News Reporter-Staff News Editor at Biotech Week- BiondVax Pharmaceuticals Ltd., developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced they will co-host the Annual UNISEC Consortium Meeting, which will take place next week in Jerusalem, Israel.
2/21/18 - Bioreactors Market Trends Will Double by 2024: Zion Market Research, the market research group announced the analysis report titled 'Bioreactors Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20162024'
Sarasota, FL 02/21/2018 Global Bioreactors Market: Overview. Bioreactor or fermenter is requisite equipment required for bioprocessing. Bioreactors are specifically constructed systems or vessels that can support a biologically live environment, as a specific surrounding is required for the cells to grow.
2/21/18 - Boston Children`s Hospital Accelerates Data-Driven Approach to Clinical Research by Joining the TriNetX Global Health Research Network [All Iraq News Agency (AIN)]
Boston Children`s Hospital, the top ranked pediatric hospital in the nation according to U.S. News and World Report, has joined the TriNetX global health research network to further its efforts at bringing a more data-driven approach to clinical research. "Infusing a data-driven approach into the conversation between research institutions and indu
2/21/18 - CDC panel approves new hepatitis B vaccine for adults
A new vaccine to prevent hepatitis B in adults has received unanimous recommendation from a Centers for Disease Control and Prevention advisory committee, Dynavax Technologies Corporation announced Wednesday. "With the ACIP's recommendation, Heplisav-B has cleared an important milestone needed to position Dynavax to meet our long-term commercial..
2/21/18 - Celgene Corporation - OTEZLA Phase III Data Showed Significant Improvements in Patients with Active Behcet's Disease with Oral Ulcers
SUMMIT, N.J.- Celgene Corporation today announced that data from the phase III RELIEF clinical trial of OTEZLA in patients with active Behcet's Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology Annual Meeting. OTEZLA is Celgene's oral selective inhibitor of phosphodiesterase 4.
2/21/18 - Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that the first patient has been dosed in its Phase 3 VICTORY-1 clinical trial of CNTX-4975, a synthetic, ultra-pure injection of trans-capsaicin, for the treatment of chronic moderate to seve
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement